 Sandra Luna-Fineman
Concepts (287)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Retinoblastoma | 9 | 2023 | 33 | 3.140 |
Why?
| | Retinal Neoplasms | 7 | 2023 | 26 | 2.640 |
Why?
| | Hodgkin Disease | 6 | 2023 | 139 | 2.190 |
Why?
| | Neoplasms | 18 | 2024 | 2661 | 1.050 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 8 | 2023 | 1688 | 0.960 |
Why?
| | Wilms Tumor | 3 | 2025 | 86 | 0.880 |
Why?
| | Vincristine | 4 | 2023 | 116 | 0.650 |
Why?
| | Eye Enucleation | 1 | 2019 | 12 | 0.650 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2021 | 99 | 0.640 |
Why?
| | Child | 42 | 2025 | 21999 | 0.630 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2019 | 288 | 0.610 |
Why?
| | Developing Countries | 8 | 2025 | 307 | 0.580 |
Why?
| | Guatemala | 9 | 2024 | 326 | 0.580 |
Why?
| | Medical Oncology | 6 | 2024 | 291 | 0.570 |
Why?
| | Time-to-Treatment | 1 | 2019 | 204 | 0.560 |
Why?
| | Refusal to Treat | 1 | 2017 | 17 | 0.540 |
Why?
| | Neoadjuvant Therapy | 1 | 2019 | 403 | 0.530 |
Why?
| | Burkitt Lymphoma | 1 | 2017 | 60 | 0.520 |
Why?
| | Child, Preschool | 24 | 2025 | 11080 | 0.500 |
Why?
| | Malnutrition | 1 | 2017 | 82 | 0.500 |
Why?
| | Etoposide | 5 | 2023 | 157 | 0.490 |
Why?
| | Carboplatin | 4 | 2023 | 143 | 0.460 |
Why?
| | Antineoplastic Agents | 3 | 2023 | 2135 | 0.460 |
Why?
| | Cyclophosphamide | 4 | 2023 | 248 | 0.450 |
Why?
| | Kidney Neoplasms | 3 | 2025 | 401 | 0.400 |
Why?
| | Infant | 16 | 2025 | 9451 | 0.390 |
Why?
| | Doxorubicin | 3 | 2023 | 365 | 0.380 |
Why?
| | Leukemia, Myeloid, Acute | 2 | 2017 | 622 | 0.380 |
Why?
| | Sarcoma, Ewing | 2 | 2025 | 96 | 0.370 |
Why?
| | Neoplasm Staging | 7 | 2019 | 1374 | 0.370 |
Why?
| | Eye Neoplasms | 1 | 2011 | 18 | 0.370 |
Why?
| | Survival Rate | 8 | 2025 | 1970 | 0.370 |
Why?
| | Lymphoma, Follicular | 4 | 2016 | 40 | 0.360 |
Why?
| | Positron-Emission Tomography | 3 | 2017 | 295 | 0.330 |
Why?
| | Adolescent | 26 | 2025 | 21499 | 0.320 |
Why?
| | Bone Neoplasms | 2 | 2025 | 248 | 0.320 |
Why?
| | Humans | 53 | 2025 | 137294 | 0.300 |
Why?
| | Contrast Media | 4 | 2018 | 462 | 0.290 |
Why?
| | Biomarkers, Tumor | 5 | 2025 | 1274 | 0.290 |
Why?
| | Male | 32 | 2025 | 67560 | 0.280 |
Why?
| | Germ-Line Mutation | 2 | 2022 | 172 | 0.280 |
Why?
| | Female | 34 | 2025 | 73052 | 0.270 |
Why?
| | Magnetic Resonance Imaging | 7 | 2018 | 3568 | 0.270 |
Why?
| | Gadolinium | 2 | 2018 | 82 | 0.260 |
Why?
| | Central America | 2 | 2019 | 24 | 0.250 |
Why?
| | Disease-Free Survival | 3 | 2021 | 687 | 0.240 |
Why?
| | Myelodysplastic Syndromes | 2 | 1999 | 135 | 0.240 |
Why?
| | Hematology | 2 | 2024 | 20 | 0.240 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 368 | 0.230 |
Why?
| | Coronavirus Infections | 2 | 2020 | 359 | 0.230 |
Why?
| | Genetic Heterogeneity | 1 | 2025 | 59 | 0.230 |
Why?
| | Clonal Evolution | 1 | 2025 | 45 | 0.230 |
Why?
| | Pediatrics | 5 | 2024 | 1113 | 0.220 |
Why?
| | Fluorodeoxyglucose F18 | 2 | 2015 | 135 | 0.220 |
Why?
| | Tumor Microenvironment | 3 | 2025 | 674 | 0.210 |
Why?
| | Multimodal Imaging | 4 | 2018 | 116 | 0.200 |
Why?
| | Infant, Newborn | 8 | 2021 | 6054 | 0.200 |
Why?
| | Prognosis | 8 | 2025 | 4026 | 0.200 |
Why?
| | Single-Cell Analysis | 1 | 2025 | 311 | 0.190 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2021 | 1058 | 0.180 |
Why?
| | Lymphatic Irradiation | 1 | 2021 | 10 | 0.180 |
Why?
| | Libraries, Medical | 1 | 2021 | 11 | 0.180 |
Why?
| | RNA, Neoplasm | 1 | 2021 | 82 | 0.180 |
Why?
| | Treatment Refusal | 2 | 2019 | 89 | 0.180 |
Why?
| | Prospective Studies | 6 | 2023 | 7595 | 0.170 |
Why?
| | Circulating Tumor DNA | 1 | 2021 | 34 | 0.170 |
Why?
| | Disease Management | 2 | 2020 | 627 | 0.170 |
Why?
| | Pandemics | 4 | 2022 | 1623 | 0.170 |
Why?
| | Fellowships and Scholarships | 1 | 2024 | 306 | 0.170 |
Why?
| | DNA Replication | 1 | 2022 | 238 | 0.160 |
Why?
| | Herpesvirus 4, Human | 1 | 2021 | 167 | 0.160 |
Why?
| | DNA Repair | 1 | 2022 | 231 | 0.160 |
Why?
| | Chemotherapy, Adjuvant | 2 | 2019 | 390 | 0.160 |
Why?
| | Ferrosoferric Oxide | 2 | 2018 | 27 | 0.160 |
Why?
| | B7-H1 Antigen | 1 | 2022 | 218 | 0.160 |
Why?
| | Chemoradiotherapy | 1 | 2021 | 226 | 0.160 |
Why?
| | Chromosomes, Human, Pair 7 | 2 | 1999 | 18 | 0.160 |
Why?
| | Monosomy | 2 | 1999 | 12 | 0.160 |
Why?
| | Feasibility Studies | 1 | 2023 | 949 | 0.150 |
Why?
| | Myeloproliferative Disorders | 1 | 1999 | 27 | 0.150 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2021 | 189 | 0.150 |
Why?
| | Information Dissemination | 1 | 2021 | 217 | 0.150 |
Why?
| | Leukemia | 2 | 2017 | 238 | 0.150 |
Why?
| | Chromosome Aberrations | 2 | 1999 | 155 | 0.150 |
Why?
| | Practice Guidelines as Topic | 2 | 2025 | 1577 | 0.140 |
Why?
| | Fractures, Spontaneous | 1 | 2017 | 15 | 0.140 |
Why?
| | Bone Marrow Diseases | 1 | 2017 | 19 | 0.140 |
Why?
| | Nicaragua | 1 | 2017 | 7 | 0.140 |
Why?
| | Disease Progression | 3 | 2021 | 2752 | 0.140 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2018 | 99 | 0.140 |
Why?
| | Retrospective Studies | 8 | 2022 | 15639 | 0.140 |
Why?
| | Orbital Diseases | 1 | 1997 | 32 | 0.140 |
Why?
| | Osteonecrosis | 1 | 2017 | 25 | 0.140 |
Why?
| | Histiocytosis, Langerhans-Cell | 1 | 1997 | 38 | 0.140 |
Why?
| | Biopsy, Needle | 1 | 1997 | 189 | 0.130 |
Why?
| | Bone Diseases | 1 | 2017 | 62 | 0.130 |
Why?
| | Delivery of Health Care | 2 | 2021 | 944 | 0.130 |
Why?
| | Lymphoma | 1 | 2018 | 208 | 0.130 |
Why?
| | DNA Mutational Analysis | 2 | 2016 | 400 | 0.130 |
Why?
| | Edema | 1 | 2017 | 130 | 0.130 |
Why?
| | Lymphoma, B-Cell, Marginal Zone | 1 | 2016 | 13 | 0.130 |
Why?
| | Risk Factors | 6 | 2021 | 10368 | 0.130 |
Why?
| | Brain Diseases | 1 | 2017 | 141 | 0.130 |
Why?
| | Morbidity | 1 | 2017 | 324 | 0.120 |
Why?
| | Income | 2 | 2023 | 203 | 0.120 |
Why?
| | Bone Marrow | 1 | 2017 | 286 | 0.120 |
Why?
| | Health Services Needs and Demand | 1 | 2017 | 273 | 0.120 |
Why?
| | Sarcoma | 1 | 2018 | 191 | 0.120 |
Why?
| | Treatment Outcome | 6 | 2023 | 10800 | 0.120 |
Why?
| | Chelating Agents | 1 | 2015 | 75 | 0.120 |
Why?
| | Aftercare | 1 | 2017 | 209 | 0.120 |
Why?
| | LIM Domain Proteins | 1 | 2015 | 21 | 0.120 |
Why?
| | Leukemia, Myeloid | 1 | 1995 | 45 | 0.120 |
Why?
| | Myeloablative Agonists | 1 | 2014 | 22 | 0.120 |
Why?
| | Chromosome Deletion | 1 | 1995 | 115 | 0.110 |
Why?
| | Lymphoma, B-Cell | 2 | 1992 | 106 | 0.110 |
Why?
| | Indians, Central American | 1 | 2014 | 6 | 0.110 |
Why?
| | INDEL Mutation | 1 | 2014 | 16 | 0.110 |
Why?
| | Gamma Rays | 1 | 2014 | 57 | 0.110 |
Why?
| | Young Adult | 10 | 2022 | 13163 | 0.110 |
Why?
| | Whole Body Imaging | 1 | 2014 | 25 | 0.110 |
Why?
| | Retinoblastoma Protein | 1 | 2014 | 57 | 0.110 |
Why?
| | Central Venous Catheters | 1 | 2014 | 51 | 0.110 |
Why?
| | Receptors, Complement 3d | 1 | 2015 | 141 | 0.110 |
Why?
| | Combined Modality Therapy | 3 | 2013 | 1237 | 0.110 |
Why?
| | Neutropenia | 1 | 2014 | 146 | 0.110 |
Why?
| | Heart Diseases | 1 | 2017 | 359 | 0.110 |
Why?
| | Transplantation, Autologous | 1 | 2014 | 238 | 0.110 |
Why?
| | Latin America | 3 | 2022 | 95 | 0.100 |
Why?
| | Transplantation Conditioning | 1 | 2014 | 170 | 0.100 |
Why?
| | Immunoglobulin M | 1 | 2015 | 288 | 0.100 |
Why?
| | Radiopharmaceuticals | 1 | 2014 | 178 | 0.100 |
Why?
| | Point Mutation | 1 | 2014 | 235 | 0.100 |
Why?
| | Fever | 1 | 2014 | 308 | 0.100 |
Why?
| | Glucocorticoids | 1 | 2017 | 596 | 0.100 |
Why?
| | Cerebellar Neoplasms | 1 | 2014 | 155 | 0.100 |
Why?
| | Down Syndrome | 1 | 2019 | 491 | 0.100 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2014 | 153 | 0.100 |
Why?
| | Patient Safety | 1 | 2016 | 309 | 0.100 |
Why?
| | Medulloblastoma | 1 | 2014 | 196 | 0.100 |
Why?
| | Bacterial Infections | 1 | 2014 | 251 | 0.100 |
Why?
| | Time Factors | 2 | 2021 | 6818 | 0.100 |
Why?
| | Bacteremia | 1 | 2014 | 211 | 0.090 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 1992 | 173 | 0.090 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2015 | 429 | 0.090 |
Why?
| | Major Histocompatibility Complex | 1 | 1992 | 227 | 0.090 |
Why?
| | Adult | 10 | 2022 | 37724 | 0.090 |
Why?
| | Neoplasm Proteins | 1 | 2015 | 434 | 0.090 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2019 | 2195 | 0.090 |
Why?
| | Proto-Oncogene Proteins | 1 | 2015 | 647 | 0.090 |
Why?
| | Tomography, X-Ray Computed | 3 | 2018 | 2679 | 0.090 |
Why?
| | Crohn Disease | 1 | 2014 | 244 | 0.090 |
Why?
| | Proportional Hazards Models | 1 | 2014 | 1260 | 0.090 |
Why?
| | Incidence | 2 | 2014 | 2808 | 0.090 |
Why?
| | Macrophages | 1 | 2018 | 1544 | 0.080 |
Why?
| | Dura Mater | 1 | 2009 | 31 | 0.080 |
Why?
| | Promoter Regions, Genetic | 1 | 2014 | 1250 | 0.080 |
Why?
| | Rhabdomyosarcoma, Alveolar | 1 | 2008 | 11 | 0.080 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2014 | 805 | 0.080 |
Why?
| | DNA Methylation | 1 | 2014 | 644 | 0.080 |
Why?
| | Rhabdomyosarcoma, Embryonal | 1 | 2008 | 22 | 0.080 |
Why?
| | Community-Institutional Relations | 1 | 2009 | 98 | 0.070 |
Why?
| | Adrenal Gland Neoplasms | 1 | 2009 | 89 | 0.070 |
Why?
| | Meningeal Neoplasms | 1 | 2009 | 100 | 0.070 |
Why?
| | Neuroblastoma | 1 | 2009 | 160 | 0.070 |
Why?
| | Survival Analysis | 3 | 2022 | 1321 | 0.070 |
Why?
| | Idarubicin | 1 | 2007 | 5 | 0.070 |
Why?
| | Vidarabine | 1 | 2007 | 33 | 0.070 |
Why?
| | Follow-Up Studies | 1 | 2017 | 5125 | 0.070 |
Why?
| | Soft Tissue Neoplasms | 1 | 2008 | 115 | 0.070 |
Why?
| | Healthcare Disparities | 1 | 2014 | 652 | 0.070 |
Why?
| | Betacoronavirus | 2 | 2020 | 267 | 0.070 |
Why?
| | Adrenal Cortex Hormones | 1 | 1990 | 556 | 0.060 |
Why?
| | Virus Shedding | 1 | 2006 | 48 | 0.060 |
Why?
| | Interleukin-2 | 1 | 2007 | 455 | 0.060 |
Why?
| | Cross-Sectional Studies | 3 | 2022 | 5436 | 0.060 |
Why?
| | Poliovirus | 1 | 2006 | 85 | 0.060 |
Why?
| | Health Services Accessibility | 1 | 2013 | 982 | 0.060 |
Why?
| | Mutation | 1 | 2016 | 3956 | 0.060 |
Why?
| | Societies, Medical | 2 | 2020 | 822 | 0.060 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2025 | 80 | 0.060 |
Why?
| | Anti-Bacterial Agents | 1 | 2014 | 1805 | 0.050 |
Why?
| | Sequence Analysis, RNA | 1 | 2025 | 452 | 0.050 |
Why?
| | Suspensions | 1 | 2022 | 36 | 0.050 |
Why?
| | Sensitivity and Specificity | 2 | 2017 | 1946 | 0.050 |
Why?
| | Proto-Oncogene Protein c-fli-1 | 1 | 2021 | 25 | 0.040 |
Why?
| | United States | 2 | 2023 | 14742 | 0.040 |
Why?
| | RNA-Binding Protein EWS | 1 | 2021 | 26 | 0.040 |
Why?
| | Reproducibility of Results | 2 | 2021 | 3283 | 0.040 |
Why?
| | Cancer Care Facilities | 2 | 2014 | 38 | 0.040 |
Why?
| | India | 1 | 2021 | 193 | 0.040 |
Why?
| | Translocation, Genetic | 1 | 2021 | 105 | 0.040 |
Why?
| | Remission Induction | 2 | 2009 | 288 | 0.040 |
Why?
| | Health Resources | 1 | 2021 | 122 | 0.040 |
Why?
| | Radiation Dosage | 1 | 2021 | 175 | 0.040 |
Why?
| | Transcriptional Regulator ERG | 1 | 2019 | 18 | 0.040 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 2019 | 44 | 0.040 |
Why?
| | Fetal Hemoglobin | 1 | 1999 | 7 | 0.040 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2021 | 215 | 0.040 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2025 | 1399 | 0.040 |
Why?
| | Withholding Treatment | 2 | 2011 | 77 | 0.040 |
Why?
| | Principal Component Analysis | 1 | 2019 | 195 | 0.040 |
Why?
| | Vietnam | 1 | 2018 | 28 | 0.040 |
Why?
| | Rwanda | 1 | 2018 | 29 | 0.040 |
Why?
| | Genetic Predisposition to Disease | 2 | 2019 | 2419 | 0.040 |
Why?
| | Health Care Surveys | 1 | 2020 | 564 | 0.040 |
Why?
| | Polymerase Chain Reaction | 1 | 2021 | 1061 | 0.040 |
Why?
| | Gene Expression Profiling | 1 | 2025 | 1774 | 0.040 |
Why?
| | Risk Assessment | 2 | 2021 | 3439 | 0.040 |
Why?
| | Histiocytes | 1 | 1997 | 7 | 0.040 |
Why?
| | California | 1 | 2019 | 424 | 0.040 |
Why?
| | S100 Proteins | 1 | 1997 | 37 | 0.030 |
Why?
| | Haplotypes | 1 | 2019 | 493 | 0.030 |
Why?
| | Antigens, CD1 | 1 | 1997 | 58 | 0.030 |
Why?
| | Systems Integration | 1 | 2017 | 37 | 0.030 |
Why?
| | Registries | 2 | 2021 | 2016 | 0.030 |
Why?
| | Gene Deletion | 1 | 1999 | 392 | 0.030 |
Why?
| | Immunoenzyme Techniques | 1 | 1997 | 219 | 0.030 |
Why?
| | Consensus | 1 | 2020 | 680 | 0.030 |
Why?
| | Orbit | 1 | 1997 | 70 | 0.030 |
Why?
| | Observer Variation | 1 | 2017 | 345 | 0.030 |
Why?
| | Comorbidity | 1 | 2021 | 1624 | 0.030 |
Why?
| | Leukemia, Radiation-Induced | 1 | 1995 | 4 | 0.030 |
Why?
| | Genes, Neurofibromatosis 1 | 1 | 1995 | 4 | 0.030 |
Why?
| | Femur | 1 | 2017 | 258 | 0.030 |
Why?
| | Genes, ras | 1 | 1995 | 97 | 0.030 |
Why?
| | Genetic Diseases, Inborn | 1 | 1995 | 42 | 0.030 |
Why?
| | Chromosome Disorders | 1 | 1995 | 43 | 0.030 |
Why?
| | Carmustine | 1 | 2014 | 50 | 0.030 |
Why?
| | Germinal Center | 1 | 2015 | 58 | 0.030 |
Why?
| | Adalimumab | 1 | 2014 | 48 | 0.030 |
Why?
| | Microfilament Proteins | 1 | 2015 | 131 | 0.030 |
Why?
| | Tumor Cells, Cultured | 2 | 1992 | 954 | 0.030 |
Why?
| | Neoplasms, Second Primary | 1 | 1995 | 116 | 0.030 |
Why?
| | Bone Marrow Transplantation | 1 | 2014 | 287 | 0.030 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 1992 | 41 | 0.030 |
Why?
| | Transcription Factors | 1 | 2021 | 1720 | 0.020 |
Why?
| | CD8 Antigens | 1 | 1992 | 75 | 0.020 |
Why?
| | Cancer Survivors | 1 | 2017 | 282 | 0.020 |
Why?
| | Genome-Wide Association Study | 1 | 2019 | 1434 | 0.020 |
Why?
| | Graft vs Host Disease | 1 | 2014 | 249 | 0.020 |
Why?
| | Risk | 1 | 1995 | 908 | 0.020 |
Why?
| | CD3 Complex | 1 | 1992 | 106 | 0.020 |
Why?
| | Interleukin-3 | 1 | 1992 | 25 | 0.020 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2015 | 455 | 0.020 |
Why?
| | Hematopoietic Stem Cells | 1 | 1995 | 402 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2019 | 3546 | 0.020 |
Why?
| | HIV Infections | 1 | 2006 | 2820 | 0.020 |
Why?
| | Recurrence | 1 | 2014 | 1059 | 0.020 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 1992 | 337 | 0.020 |
Why?
| | Anti-Inflammatory Agents | 1 | 2014 | 498 | 0.020 |
Why?
| | Tumor Lysis Syndrome | 1 | 1990 | 8 | 0.020 |
Why?
| | Cell Communication | 1 | 1992 | 315 | 0.020 |
Why?
| | Treatment Failure | 1 | 2011 | 354 | 0.020 |
Why?
| | Waardenburg Syndrome | 1 | 2009 | 1 | 0.020 |
Why?
| | Microphthalmia-Associated Transcription Factor | 1 | 2009 | 14 | 0.020 |
Why?
| | Adrenalectomy | 1 | 2009 | 68 | 0.020 |
Why?
| | El Salvador | 1 | 2009 | 6 | 0.020 |
Why?
| | Honduras | 1 | 2009 | 9 | 0.020 |
Why?
| | Congresses as Topic | 1 | 2011 | 234 | 0.020 |
Why?
| | Oncology Service, Hospital | 1 | 2009 | 16 | 0.020 |
Why?
| | B-Lymphocytes | 1 | 2015 | 846 | 0.020 |
Why?
| | Neural Crest | 1 | 2009 | 116 | 0.020 |
Why?
| | Mexico | 1 | 2009 | 225 | 0.020 |
Why?
| | Pulmonary Veins | 1 | 2009 | 99 | 0.020 |
Why?
| | Early Diagnosis | 1 | 2009 | 244 | 0.020 |
Why?
| | Cell Lineage | 1 | 2009 | 348 | 0.020 |
Why?
| | Immunotherapy | 1 | 1992 | 641 | 0.020 |
Why?
| | Program Development | 1 | 2009 | 365 | 0.020 |
Why?
| | Italy | 1 | 2007 | 109 | 0.020 |
Why?
| | Information Services | 1 | 2007 | 49 | 0.020 |
Why?
| | Nutrition Assessment | 1 | 2007 | 91 | 0.020 |
Why?
| | International Cooperation | 1 | 2007 | 199 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 1992 | 1431 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 2018 | 2494 | 0.010 |
Why?
| | Cooperative Behavior | 1 | 2007 | 444 | 0.010 |
Why?
| | Terminal Care | 1 | 2007 | 226 | 0.010 |
Why?
| | Feces | 1 | 2006 | 480 | 0.010 |
Why?
| | Skin Neoplasms | 1 | 2009 | 852 | 0.010 |
Why?
| | Aged | 1 | 2018 | 23851 | 0.010 |
Why?
| | Middle Aged | 1 | 2018 | 33310 | 0.010 |
Why?
| | Quality of Life | 1 | 2007 | 2885 | 0.010 |
Why?
| | Receptors, Interleukin-3 | 1 | 1992 | 5 | 0.010 |
Why?
| | Fluorescent Antibody Technique | 1 | 1992 | 388 | 0.010 |
Why?
| | Cell Division | 1 | 1992 | 796 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 1992 | 1354 | 0.000 |
Why?
| | Lymphocyte Activation | 1 | 1992 | 1150 | 0.000 |
Why?
|
|
Luna-Fineman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|